Aquestive Therapeutics
AQST
97 hedge funds and large institutions have $177M invested in Aquestive Therapeutics in 2024 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 9 closing their positions.
467% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 9
268% more capital invested
Capital invested by funds: $48.1M → $177M (+$129M)
115% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $1.97M
70% more funds holding
Funds holding: 57 → 97 (+40)
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
10.49% more ownership
Funds ownership: 35.63% → 46.12% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$18.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$7.39M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$5.14M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.51M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$7.93M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$776K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$584K |
| 4 |
Two Sigma Investments
New York
|
-$374K |
| 5 |
Corient Private Wealth
Miami,
Florida
|
-$319K |
AQST Hedge Fund Activity: Q1 2024 in Review
97 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2024, worth a combined $177M — up 268% from $48.1M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new AQST positions and 9 closed out — a net gain of 42 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $18.5M. The largest seller was Armistice Capital, exiting entirely with an estimated $7.93M sold.
- 97 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2024, up from 57 in Q4 2023.
- Funds reported $177M of Aquestive Therapeutics stock for Q1 2024, up 268% quarter-over-quarter.
- 51 funds opened new Aquestive Therapeutics positions in Q1 2024 and 9 closed out, a net change of +42 holders.
- The largest Aquestive Therapeutics buyer in Q1 2024 was VR Adviser, an estimated $18.5M added.
- The largest Aquestive Therapeutics seller in Q1 2024 was Armistice Capital, an estimated $7.93M sold.
Based on aggregated 13F filings for Q1 2024.